Chapter 13
Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis
Geoffrey C. Farrell,
Geoffrey C. Farrell
Search for more papers by this authorGeoffrey C. Farrell,
Geoffrey C. Farrell
Search for more papers by this authorBook Editor(s):Juan Rodés MD,
Jean-Pierre Benhamou MD,
Andres T. Blei MD,
Jürg Reichen MD,
Mario Rizzetto MD,
Juan Rodés MD
Director General, Hospital Clinic; Professor of Medicine, University of Barcelona, Barcelona, Spain
Search for more papers by this authorJean-Pierre Benhamou MD
Professor of Hepatology, Université Denis Diderot Paris 7, Assistance Publique — Hôpitaux de Paris and Inserm U773, Service d'Hépatologie, Hôpital Beaujon, Clichy, France
Search for more papers by this authorAndres T. Blei MD
Professor of Medicine and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJürg Reichen MD
Professor of Medicine, University of Bern; Chief of Hepatology, University Hospital, Bern, Switzerland
Search for more papers by this authorMario Rizzetto MD
Professor of Gastroenterology, University of Turin, Turin, Italy
Search for more papers by this author
References
- Adler M Schaffner F (1979) Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67, 811–816.
- Ludwig J Viaggiano TR McGill DB et al. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease. Mayo Clin Proc 55, 434–438.
- James OFW Day CP (1998) Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29, 495–501.
- Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 16, 1221–1231.
- Clark JM Brancati FL Diehl AM (2002) Nonalcoholic fatty liver disease. Gastroenterology 122, 1649–1657.
- Farrell GC (2003) Okuda Lecture. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region. J Gastroenterol Hepatol 18, 124–138.
- Neuschwander-Tetri BA Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37, 1202–1219.
- GC Farrell J George P Hall M de la et al. (eds) (2005) Fatty Liver Disease. NASH and Related Disorders. Malden, MA: Blackwell Publishing, pp. 1–319.
- Javor ED Ghany MG Cochran EK et al. (2005) Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41, 753–760.
- Matteoni CA Younossi ZM Gramlich T et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413–1419.
- Kleiner DE Brunt EM Van Natta M et al. (2005) Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41, 1313–1321.
- Brunt EM Janney CG Di Bisceglie AM et al. (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94, 2467–2474.
- Hall P de la M Kirsch R (2005) Pathology of steatosis, NASH and related conditions. In: GC Farrell, J George, P Hall de la. et al. (eds) Fatty Liver Disease. NASH and Related Disorders. Malden, MA: Blackwell Publishing, pp. 13–22.
- Mendler MH Kanel G Govindarajan S (2005) Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 25, 294–304.
- Ratziu V Charlotte F Heurtier A et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898–1906.
- Gramlich T Kleiner DE McCullough AJ et al. (2004) Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 35, 196–199.
- McCullough AJ (2005) The epidemiology and risk factors of NASH. In: GC Farrell, J George, P Hall de la. et al. (eds) Fatty Liver Disease. NASH and Related Disorders. Malden, MA: Blackwell Publishing, pp. 23–37.
- George DK Goldwurm S MacDonald GA et al. (1998) Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114, 311–318.
- Bonkovsky HL Jawhid Q Tortorelli K et al. (1999) Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31, 421–429.
- Norton R Batey R Dwyer T et al. (1987) Alcohol consumption and the risk of alcohol related cirrhosis in women. Br Med J 295, 80–82.
- National Institutes of Health Consensus Development Conference Statement (2002) Management of Hepatitis C: 2002. Hepatology 36 (Suppl. 1), S3–S21.
- Hayashi PH Harrison SA Torgerson S et al. (2004) Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am J Gastroenterol 99, 76–81.
- Nomura H Kashiwagi S Hayashi J et al. (1988) Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 27, 142–149.
- Bellanti S Saccoccio G Masatti F et al. (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132, 112–117.
- Hasan I Gani RA Machmud R et al. (2002) Prevalence and risk factors for nonalcoholic fatty liver in Indonesia. J Gastroenterol Hepatol 17 (Suppl), A154.
- Browning JD Szczepaniak LS Dobbins R et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395.
- Patt CH Yoo HY Dibadji K et al. (2003) Prevalence of transaminase abnormalities in asymptomatic healthy subjects. Dig Dis Sci 48, 797–801.
- Hilden M Christoffersen P Juhl E et al. (1977) Liver histology in a ‘normal’ population: examination of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12, 593–599.
- Ground KE (1982) Liver biopsy in review. Aviat Space Environ Med 53, 14–18.
- Wanless IR Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12, 1106–1110.
- Marcos A Fisher RA Jam JM et al. (2000) Selection and outcome of living donors for adult right lobe. Transplantation 69, 2410–2415.
- Hwang S Lee SG Jang SJ et al. (2004) The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl 10, 721–727.
- Dixon JB Bhathal PS O'Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121, 91–100.
- Marceau P Biron S Hould FS et al. (1999) Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84, 1513–1517.
- Del Gaudio A Boschi L Del Gaudio GA et al. (2001) Liver damage in obese persons. Obes Surg 11, 254–257.
- Lucyckx FA Desaive C Tiry A et al. (1998) Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes 22, 222–226.
- Silverman EM Sapala JA Appelman HD (1995) Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 104, 23–31.
- Roberts EA (2002) Steatohepatitis in children. Best Pract Res Clin Gastroenterol 16, 749–765.
- Lavine JE Schwimmer JB (2005) NAFLD/NASH in children. In: GC Farrell, J George, P Hall de la. et al. (eds) Fatty Liver Disease. NASH and Related Disorders. Malden, MA: Blackwell Publishing, pp. 229–240.
- Manton ND Lipsett J Moore DJ et al. (2000) Non-alcoholic steato-hepatitis in children and adolescents. Med J Aust 173, 476–479.
- Bacon BR Farahvash MJ Janney CG et al. (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107, 1103–1109.
- Chitturi S Abeygunasekera S Farrell GC et al. (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35, 373–378.
- Pagano G Pacini G Musso G et al. (2002) Nonalcoholic steatohepatitis, insulin resistance and metabolic syndrome: further evidence for an etiologic association. Hepatology 35, 367–372.
- Marchesini G Bugianesi E Forlani G et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917–923.
- Angelico F Del Ben M Conti R et al. (2003) Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 18, 1115–1117.
- Kral JG Schaffner F Pierson RN Jr et al. (1993) Body fat topography as an independent predictor of fatty liver. Metabolism 42, 548–551.
- Omagari KH Kadokawa Y Masuda J et al. (2002) Fatty liver in nonalcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17, 1089–1105.
- Park SH Jeon WK Kim SH et al. (2006) Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 21, 138–141.
- Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497.
- Struben VMD Hespenheide EE Caldwell SH (2000) Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108, 9–13.
- Petersen KF Befroy D Dufour S et al. (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140–1142.
- Poynard T Ratziu V Benhamou Y et al. (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20, 47–55.
- Chitturi S Farrell GC (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21, 27–41.
- Capron J-P Delamarre J Dupas J-L et al. (1982) Fasting in obesity: another cause of liver injury with alcoholic hyaline. Dig Dis Sci 27, 265–268.
- Angulo P Keach JC Batts KP et al. (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30, 1356–1362.
- Harrison SA Torgerson S Hayashi PH (2003) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98, 2042–2047.
- Ratziu V Bonhay L Di Martino V et al. (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35, 1485–1493.
- Mofrad P Contos MJ Haque M et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37, 1286–1292.
- Ioannou GN Weiss NS Boyko EJ et al. (2005) Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 128, 627–635.
- Samuel VT Shulman G (2005) Insulin resistance in NAFLD: potential mechanisms and therapies. In: GC Farrell, J George, P Hall de la. et al. (eds) Fatty Liver Disease. NASH and Related Disorders. Malden, MA: Blackwell Publishing, pp. 38–54.
- Wanless IR Shiota K (2004) The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 24, 99–106.
- Park SH Kim BI Yun JW et al. (2004) Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 19, 694–698.
- Hui J Farrell GC Kench JG et al. (2004) High sensitivity CRP protein values do not reliably predict the severity of histological change in NAFLD (letter). Hepatology 39, 1458–1459.
- Tilg H Diehl AM (2000) Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 343, 1467–1476.
- Hui J Hodge A Farrell GC et al. (2004) Beyond insulin resistance in NASH: TNF-alpha or adiponectin. Hepatology 40, 19–22.
- Bugianesi E Pagotto U Manini R et al. (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to disease severity. J Clin Endocrinol Metab 90, 3498–3504.
- Diehl AM Li ZP Lin HZ et al. (2005) Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54, 303–306.
- Bugianesi E Manzini P D'Antico S et al. (2004) Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepatology 39, 179–187.
- Younossi ZM Gramlich T Bacon BR et al. (1999) Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30, 847–850.
- Chitturi C Weltman M Farrell GC et al. (2002) HFE mutations, hepatic iron, and fibrosis: ethnic-specific associations of NASH with C282Y but not with fibrotic severity. Hepatology 36, 142–148.
- Saadeh S Younossi ZM Remer EM et al. (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123, 745–750.
- Friedman LS (2004) Controversies in liver biopsy: who, where, when, how, why. Curr Gastroenterol Rep 6, 30–36.
- Powell EE Cooksley WGE Hanson R et al. (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11, 74–80.
- Falck-Ytter Y Younossi ZM Marchesini G et al. (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21, 17–26.
- Caldwell SH Hespenheide EE (2002) Subacute liver failure in obese women. Am J Gastroenterol 97, 2058–2062.
- Hui JM Kench JG Chitturi S et al. (2003) Long-term outcomes of cirrhosis in non-alcoholic steatohepatitis compared to hepatitis C. Hepatology 38, 873–881.
- Brun E Nelson RG Bennett PH et al. (2000) Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 23, 1119–1123.
- Lowell BB Shulman GG (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307, 384–387.
- Samuel VT Liu Z-X Qu X et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279, 32345–32353.
- Kim JK Fillmore JJ Chen Y et al. (2001) Tissue-specific overexpres-sion of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 98, 7522–7527.
- Kraegen EW Clark PW Jenkins AB et al. (1991) Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40, 1397–1403.
- Browning JD Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114, 147–152.
- Sanyal AJ Campbell-Sargent C Mirshahi F et al. (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183–1192.
- Caldwell SH Swerdlow RH Khan EM et al. (1999) Mitochondrial abnormalities in nonalcoholic steatohepatitis. J Hepatol 31, 430–434.
- Carmiel-Haggai M Cederbaum AI Nieto N (2005) A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19, 136–138.
- Masaki T Chiba S Tatsukawa H et al. (2004) Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40, 19–22.
- Xu A Wang Y Keshaw H et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112, 91–100.
- Day C James O (1998) Steatohepatitis: a tale of two ‘hits’. Gastroenterology 114, 842–845.
- Weltman MD Farrell GC Ingelman-Sundberg M et al. (1998) Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128–133.
- Chalasani N Gorski C Asghar MS et al. (2003) Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37, 544–550.
- Leclercq IA Farrell GC Field J et al. (2000) Cyp2e1 and Cyp4a as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 105, 1067–1075.
- Robertson G Leclercq I Farrell GC (2001) Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281, G1135–1139.
- Deng Q-G She H Cheng J et al. (2005) Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42, 905–914.
- de la Pena A Leclercq I Field J et al. (2005) NF-KB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129, 1663–1674.
- George J Pera N Phung N et al. (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39, 756–764.
- McCuskey R Ito Y Robertson GR et al. (2004) Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 40, 386–393.
- Lavine JE (2000) Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J Pediatr 136, 734–738.
- Burke A Lucey MR (2005) NAFLD, NASH and orthotopic liver transplantation. In: GC Farrell, J George, P Hall de la. et al. (eds) Fatty Liver Disease. NASH and Related Disorders. Malden, MA: Blackwell Publishing, pp. 208–217.
- Caldwell SH Oelsner DH Iezzoni JC et al. (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29, 664–669.
- Poonawala A Nair SP Thuluvath PJ (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case study. Hepatology 32, 689–692.
- Bugianesi E Leone N Vanni E et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134–140.
- Marrero JA Fontana RJ Su GL et al. (2002) NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36, 1349–1354.
- Shimada M Hashimoto E Taniai M et al. (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37, 154–160.
- El-Serag HB Tran T Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460–468.
- Davila J Morgan RO Shaib Y et al. (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54, 533–539.
- Hourigan LF Macdonald GA Purdie D et al. (1999) Fibrosis in chronic hepatitis C correlates with body mass index and steatosis. Hepatology 29, 1215–1219.
- Hwang SJ Luo JC Chu CW et al. (2001) Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 16, 190–195.
- Hui JM Kench J Farrell GC et al. (2002) Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17, 873–881.
- Monto A Alonzo J Watson JJ et al. (2002) Steatosis in hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. Hepatology 36, 729–736.
- Kumar D Farrell GC Fung C et al. (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36, 1266–1272.
- Hui J Sud A Farrell GC et al. (2003) Insulin resistance is associated with chronic hepatitis C virus infection fibrosis progression. Gastroenterology 125, 1695–1704.
- Powell EE Jonsson JR Clouston AD (2005) Steatosis: co-factor in other liver diseases. Hepatology 42, 5–13.
- Poynard T Ratziu V McHutchison J et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38, 75–85.
- Kawaguchi T Yoshida T Harada M et al. (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165, 1499–1508.
- Shintani Y Fujie H Miyoshi H et al. (2004) Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126, 840–848.
- Mehta SH Brancati FL Strathdee SA et al (2003) Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38, 50–56.
- Bressler BL Guindi M Tomlinson G et al. (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38, 639–644.
- Patton HM Patel K Behling C et al. (2004) The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40, 484–490.
- D'Souza R Sabin CA Foster GR (2005) Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100, 1509–1515.
- Hickman IJ Clouston AD MacDonald GA et al. (2002) Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51, 89–94.
- Hickman IJ Jonsson JR Prins JB et al. (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin and quality of life. J Hepatol 53, 413–419.
- Naveau S Giraud V Borotto E et al. (1997) Excess weight risk factor for alcoholic liver disease. Hepatology 25, 108–111.
- Tuomilehto J Lindstrom J Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344, 1343–1350.
- Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, 393–403.
- Palmer M Schaffner F (1990) Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99, 1408–1413.
- Ueno T Sugawara H Sujaku K et al. (1997) Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27, 103–107.
- Angulo P (2005) Management of NASH: current and future perspectives on treatment. In: GC Farrell, J George, P Hall de la. et al. (eds) Fatty Liver Disease. NASH and Related Disorders. Malden, MA: Blackwell Publishing, pp. 194–207.
- Dixon JB Bhathal PS Hughs NR et al. (2004) Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39, 1647–1654.
- Kral JG Thung SN Biron S et al. (2004) Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135, 48–58.
- Ip E Farrell G Hall P et al. (2004) Administration of the potent PPARoc agonist, Wy14,643, reverses nutritional fibrosis and steato-hepatitis in mice. Hepatology 39, 1286–1296.
- Laurin J Lindor KD Crippin JS et al. (2004) Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23, 1464–1467.
- Saibara T Onishi S Ogawa Y et al. (1999) Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 353, 1802.
- Neuschwander-Tetri BA Brunt EM Wehmeier KR et al. (2003) Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008–1017.
- Pomrat K Lutchman G Uwaifo GI et al. (2004) A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 39, 188–196.
- Marchesini G Brizi M Bianchi G et al. (2001) Metformin in nonalcoholic steatohepatitis. Lancet 358, 893–894.
- Sanyal AJ Mofrad PS Contos MJ et al. (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2, 1107–1115.
- Hasegawa T Yoneda M Nakamura K et al. (2001) Plasma transforming growth factor-P1 level and efficacy of oc-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15, 1667–1672.
- Harrison SA Togerson S Hayashi P et al. (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 98, 2485–2490.
- Miglio F Rovati LC Santoro A et al. (2000) Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. Arznei-mittelforschung 50, 722–727.
- Abdelmalek M Angulo P Jorgensen RA et al. (2001) Betaine, a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96, 2711–2717.
- Lindor KD Kowdley KV Heathcote EJ et al. (2004) Ursodeoxycholic acid for treatment of non-alcoholic steatohepatitis: results of a randomized trial. Hepatology 39, 770–778.
